Vol 3 (August 25, 2025): AME Clinical Trials Review

Quadruplet therapy for extensive-stage small cell lung cancer (ES-SCLC): does one size fit all in treatment for ES-SCLC?

Aspirin therapy for secondary prevention of atherosclerotic cardiovascular disease: should we be tailoring according to sex?

Dual attack on multiple myeloma: targeting BCMA and CD19

The CLL2-BAAG trial provides further evidence supporting a minimal residual disease driven approach and triple therapy in relapsed chronic lymphocytic leukaemia

Is there a role for triple chemotherapy in advanced biliary tract cancer?

Abiraterone + olaparib in metastatic castration-resistant prostate cancer: tolerable, not toxic

The UNION trial: open the door to immune checkpoint inhibitors for proficient mismatch repair/microsatellite stability rectal cancer?

Assessing the UNICANCER-PRODIGE 23 trial through the lens of nonoperative management

Advancing HER2-positive breast cancer treatment: the promise and challenges of trastuzumab deruxtecan over trastuzumab emtansine—DESTINY-Breast03 trial

Balancing treatment efficacy and complications in early-onset locally advanced rectal cancer

Transforming post-surgical lung cancer recovery: app-based approach to telerehabilitation

Exploring the role of triplet therapy in relapsed chronic lymphocytic leukemia (CLL) and an emerging role for ctDNA in CLL: key takeaways from the CLL2-BAAG trial